Allied Health & Imaging · Independent exam preparation
CEBT Preparation Guide: Certified Eye Banker – Technical Study Guide
Practise donor eligibility, aseptic recovery, quality investigations, and graft selection with 60 CEBT concepts, 20 explained questions, and 20 recall cards.
By CertMedbry · Updated 31 October 2026
Learn to distinguish donor eligibility from surgical suitability, protect tissue during recovery and processing, investigate quality failures, and match graft layers to their intended use. These 60 selected concepts cover all five official domains in approximate blueprint proportions. The official EBAA Exam Content Outline defines the full examination scope, including topics beyond this selective guide.
Try 20 free practice questionsWhat is the exam format?
Check the question types, timing and outline before planning your revision.
Which certification and examination does this guide cover?
This guide covers Certified Eye Banker – Technical (CEBT), awarded by the Eye Bank Association of America. The older workbook label Certified Eye Bank Technician maps to this current designation. Candidates take the Eye Banker Certification Examination and complete practical competency verification. Certified Eye Banker (CEB) uses the same written examination but does not require performance of a technical procedure. Neither designation is an RN or advanced practice nursing examination.
EBAA Certification Exam · EBAA Criteria for Certification and Recertification of Eye Bankers
How many questions are there, how long is the examination, and what score is required?
The issuer describes 250 multiple-choice questions and a four-hour limit. The July 2025 handbook states a passing score of 187 and labels this 75%; the certification page also states 187. The supplied documents do not identify a separate scored/pretest question split. They do not establish additional item styles beyond multiple-choice questions.
EBAA Certification Exam · EBAA Criteria for Certification and Recertification of Eye Bankers
How is the examination delivered, and is it adaptive?
Professional Testing Corporation manages the examination, and Prometric delivers it electronically at testing centers or through remote proctoring. The supplied issuer documents do not describe computer adaptive testing. The questions in this guide are independent four-option, single-best-answer drills and do not reproduce the examination delivery system.
EBAA Certification Exam · EBAA Criteria for Certification and Recertification of Eye Bankers
Which blueprint applies, and what are its dates and weights?
The PDF outline linked from EBAA’s certification page agrees with the July 2025 handbook: Anatomy and Physiology 12%; Quality Assurance and Control 24%; Donor-Related Issues 20%; Technical Procedures 24%; Tissue-Related Procedures 20%. The supplied issuer documents were checked on October 30, 2026. The standalone outline has no printed version or effective date; its URL folder does not establish one. The separately accessible HTML outline has an older organization. This guide follows the linked PDF.
EBAA Exam Content Outline · EBAA Criteria for Certification and Recertification of Eye Bankers · CEBT Exam Content Outline
What eligibility and practical requirements distinguish CEBT?
The issuer requires a high school degree or GED and at least six months of qualifying transplant organization experience within the preceding two years, with active involvement in procurement or processing and required recommendations. CEBT applicants also submit signed Practical Performance Competency Verification. The July 2025 handbook lists corneal excision, laboratory microkeratome lamellar processing, or DMEK processing as approved demonstrations. Observation is live, with exceptional live remote arrangements described in the handbook.
EBAA Certification Exam · EBAA Criteria for Certification and Recertification of Eye Bankers
How are the guide, questions, and flashcards distributed?
The 60 concepts include 7 anatomy, 15 quality assurance, 12 donor, 14 technical, and 12 tissue concepts. Both the 20-question set and the 20-card set use a 2/5/4/5/4 distribution. These allocations approximate the official weights. They are selective teaching allocations, not a claim about the exact composition of an individual examination form.
Which jurisdiction and standards editions support the regulatory material?
Regulatory examples use the United States FDA HCT/P framework. Donation authorization also depends on applicable jurisdictional law. The October 17, 2024 EBAA Medical Standards and April 1, 2025 CFR annual edition are dated references, not descriptions of a latest 2026 edition. EBAA updates its standards regularly. Exact operational limits must come from applicable current requirements, validated procedures, and product instructions; this guide does not assign universal storage durations or endothelial thresholds.
EBAA Medical Standards / Procedures Manual · EBAA Medical Standards — October 17, 2024 · 21 CFR Part 1271 — April 1, 2025 annual edition
This independent CertMedbry guide targets EBAA’s Certified Eye Banker – Technical pathway. Its original questions are learning drills, carry no EBAA endorsement, and do not predict examination results.
Outline used: Verified on 2026-10-13 against EBAA's current certification page, its linked EBAA Exam Content Outline, and the Criteria for Certification and Recertification handbook labeled July 2025. The standalone outline displays no version number or effective date; its /2023/05/ URL is not an evidenced effective date. The workbook label 'Certified Eye Bank Technician (CEBT)' maps to the current designation 'Certified Eye Banker – Technical (CEBT)', earned through the Eye Banker Certification Examination and practical competency verification. The assigned slug is preserved.
60 key concepts: understand, apply and avoid the traps
Work through the questions by exam domain. Explain the answer in your own words, try the example, then check the common pitfall.
Anatomy and Physiology12%
1.How do ocular structures turn incoming light into vision?
The cornea and crystalline lens focus incoming light onto the retina. The iris regulates the pupil opening, while retinal photoreceptors convert light into electrical signals that travel through the optic nerve to the brain. Distinguish an optical problem from a neural problem: improving corneal transparency can improve light transmission, but it does not restore damaged retinal photoreceptors or optic nerve function. This distinction explains why a clear graft cannot guarantee useful recipient vision.
Apply it
A recipient has an opaque cornea and documented severe optic nerve damage. Explain that transplantation may improve the optical pathway, while the established neural damage can still limit visual benefit after the cornea becomes clear.
Common pitfall: Do not treat the cornea as the structure that detects light. It refracts and transmits light; retinal photoreceptors perform the initial sensory conversion.
2.Which focusing patterns distinguish common refractive errors?
Myopia places the focus of distant light in front of the retina when accommodation is relaxed, commonly because the eye is relatively long or its refractive power is excessive. Hyperopia places the corresponding focus behind the retina because axial length is relatively short or refractive power insufficient. Astigmatism involves unequal refractive power in different meridians. Identify the relationship between focal position, ocular shape, and refractive power rather than relying only on descriptions of near or distance blur.
Apply it
An optical diagram shows parallel rays meeting before the retinal plane. Identify myopia and explain why reducing excessive corneal refractive power can move the focal position toward the retina in an appropriately selected eye.
Common pitfall: Near blur alone does not establish hyperopia. Age-related loss of accommodation can produce similar symptoms through a different mechanism involving lens flexibility.
3.Why does presbyopia reduce near focusing ability?
Accommodation changes the crystalline lens’s refractive power to support near focus. With aging, the lens becomes harder and less flexible, reducing its ability to change shape sufficiently for nearby targets. Presbyopia therefore differs from a fixed corneal opacity and from hyperopia caused by the eye’s baseline optical geometry. A person who gradually holds reading material farther away despite preserved distance clarity provides a useful discriminating clue to reduced accommodative capacity.
Apply it
A middle-aged person reports gradually increasing difficulty reading close print but retains clear distance vision with the same correction. Link the change to reduced lens flexibility rather than assuming newly developed corneal edema or opacity.
Common pitfall: Do not attribute all refractive adjustment to the cornea. The cornea supplies substantial fixed optical power, while the lens changes power during accommodation.
4.Which five corneal layers define graft anatomy?
From anterior to posterior, the outline’s five layers are epithelium, Bowman’s membrane, stroma, Descemet membrane, and endothelium. The stroma supplies most structural substance, while Descemet membrane supports the posterior endothelial layer. Knowing the sequence allows a technician to identify which tissues a selective graft contains and which recipient layers remain. An anterior surface defect and a posterior endothelial defect occupy different anatomical compartments and can have different implications for intended graft use.
Apply it
A preparation contains Descemet membrane with its attached endothelial cells and no stromal layer. Locate it at the posterior cornea and distinguish its composition from a graft containing posterior stroma as well as endothelium.
Common pitfall: Bowman’s membrane and Descemet membrane are not interchangeable names. Their positions on opposite sides of the stroma determine their different relationships to graft preparation.
University of Iowa: Laser Refractive Surgery — Anatomy · University of Iowa: An Introduction to Corneal Transplantation
5.How do anterior and posterior corneal damage differ?
An epithelial defect affects the cornea’s anterior surface, whereas endothelial injury affects the posterior cell layer responsible for maintaining fluid balance. These findings should not be collapsed into a single description of poor tissue. Their significance depends on depth, extent, associated pathology, and the layers required for transplantation. An apparently clear anterior surface cannot establish endothelial health, and a superficial defect does not by itself prove that the posterior endothelial layer has failed.
Apply it
Two corneas look similar on gross inspection. One has a superficial epithelial defect; the other has posterior cell loss with stromal swelling. Explain why their evaluation records and potential graft applications require different anatomical reasoning.
Common pitfall: Avoid predicting suitability from surface appearance alone. A tissue can look smooth anteriorly while having important endothelial disease that requires separate evaluation.
University of Iowa: Laser Refractive Surgery — Anatomy · NEI: NIH-funded team identifies genetic underpinnings of Fuchs dystrophy
6.How does endothelial function maintain corneal hydration?
The endothelium regulates corneal hydration by moving excess fluid out of the stroma while fluid continually enters from the eye’s interior. This balance depends on living endothelial cells and energy-dependent ion transport. When endothelial function becomes inadequate, fluid accumulates, the stroma swells, and optical clarity deteriorates. Fuchs dystrophy illustrates this mechanism through progressive endothelial cell loss. Clear tissue therefore depends on physiological fluid regulation as well as an intact physical structure.
Apply it
A cornea develops diffuse stromal swelling in association with marked endothelial loss. Explain the causal sequence from reduced fluid transport to edema and impaired transparency, rather than interpreting the swelling as evidence of improved tissue hydration.
Common pitfall: More water does not make a cornea healthier. Excess stromal hydration disrupts optical performance, so preservation aims to maintain controlled hydration and cellular integrity.
NEI: NIH-funded team identifies genetic underpinnings of Fuchs dystrophy
7.Which findings distinguish edema, scarring, and graft rejection?
Edema describes excess tissue fluid, while a scar represents structural alteration that can scatter light even when hydration is controlled. Rejection is an immune process directed against transplanted donor tissue and can impair endothelial function, producing secondary edema. These terms describe different mechanisms rather than interchangeable appearances. In an untransplanted donor cornea, haze should be characterized anatomically and clinically; it cannot be called recipient graft rejection because the necessary transplant immune setting is absent.
Apply it
A donor cornea has a sharply localized stromal opacity, while a recipient graft develops edema with inflammatory findings. Distinguish a structural opacity from possible immune-mediated graft dysfunction and document the findings appropriate to each setting.
Common pitfall: Haze alone does not identify its cause. Calling every cloudy cornea rejected confuses a visual finding with an immune diagnosis requiring a transplanted graft.
NEI: NIH-funded team identifies genetic underpinnings of Fuchs dystrophy · University of Iowa: An Introduction to Corneal Transplantation
Quality Assurance and Control24%
8.How do certification, accreditation, and FDA registration differ?
Certification recognizes an individual’s qualifications, accreditation evaluates organizational functions against an accrediting body’s standards, and FDA establishment registration identifies an establishment within a regulatory system. These mechanisms answer different questions about people, organizations, and legal obligations. One does not automatically establish compliance with the others. In a quality review, identify the activity and responsible entity before selecting the relevant requirement; a technician’s credential cannot substitute for a facility’s required quality controls or regulatory responsibilities.
Apply it
An eye bank hires a certified technician and proposes using that credential as proof that a new processing location meets all facility requirements. Explain why personnel qualification and establishment compliance need separate supporting evidence.
Common pitfall: FDA registration is not a blanket endorsement of every tissue or process. Likewise, organizational accreditation does not establish that each employee is individually certified.
EBAA Accreditation Governance and Functions · EBAA Certification Exam · 21 CFR Part 1271 — April 1, 2025 annual edition
9.What demonstrates personnel competency for an assigned procedure?
Competency means that a person can perform the assigned activity correctly, including recognizing deviations and documenting essential information. Attendance at training provides evidence of exposure to instruction but does not alone demonstrate reliable performance. A defensible competency assessment connects the specific task, observed performance, acceptance criteria, evaluator, and outcome. New equipment or a materially changed procedure can create a training need even for an experienced employee whose earlier assessment covered a different method.
Apply it
An experienced recovery technician transfers to automated lamellar processing. Review whether the technician has demonstrated the new equipment setup, tissue handling, deviation response, and documentation rather than treating years of recovery experience as equivalent competency.
Common pitfall: A signed attendance sheet is tempting because it is easy to audit. It establishes participation, not necessarily the ability to execute and troubleshoot the procedure.
10.Why must operating procedures be controlled documents?
Controlled procedures establish the authorized method and make changes traceable. Approval, revision identification, effective implementation, staff communication, and removal of obsolete instructions reduce the chance that different operators perform incompatible versions of the same activity. A useful procedure also defines acceptance criteria and deviation handling. When a practice changes, the quality question is whether the change was evaluated and approved before use, rather than whether a handwritten explanation was added after the tissue was processed.
Apply it
A workbench contains an old printed procedure beside a newly approved electronic version. Remove the obsolete copy from active use, confirm staff training, and establish which version governed any tissues processed during the transition.
Common pitfall: A technically sensible shortcut can still be an uncontrolled process change. Personal experience does not replace approval, evaluation, and communication of the revised method.
11.Why must instruments be cleaned before sterilization?
Cleaning removes soil and organic material that can interfere with contact between an instrument and the sterilizing agent. Sterilization is therefore a later step in a controlled reprocessing sequence, not a substitute for soil removal. Instrument design, disassembly, accessible surfaces, and compatibility with the chosen method matter. Visible residue after cleaning indicates that the instrument is not ready to advance simply because a sterilizer cycle is available or its exposure time could be increased.
Apply it
A reusable forceps has dried material within its joint after the cleaning stage. Keep it out of the packaged load, repeat appropriate cleaning, and inspect the joint before proceeding through the validated reprocessing sequence.
Common pitfall: Extending sterilizer exposure does not reliably compensate for retained soil. The prerequisite failure concerns effective cleaning and access to contaminated surfaces.
CDC Recommendations for Disinfection and Sterilization in Healthcare Facilities
12.How should sterilization indicators be interpreted together?
Mechanical records describe cycle conditions, chemical indicators respond to specified exposure conditions, and biological indicators challenge the process with resistant microorganisms. Each supplies different evidence. A changed chemical indicator alone does not establish that every item in a load is sterile. Release decisions integrate the monitoring results with cycle selection, loading, packaging, and established acceptance criteria. Conflicting evidence requires investigation of the failed control rather than selecting whichever result supports convenient release of the instruments.
Apply it
A load has acceptable recorded cycle parameters and changed chemical indicators, but the biological monitoring result is unacceptable. Follow the established failed-cycle response and investigate the discrepancy rather than declaring the load satisfactory by majority vote.
Common pitfall: Indicator tape primarily shows exposure to a process. Treating its color change as a universal sterility certificate overlooks cycle performance and package integrity.
13.When does sterile packaging lose its protective value?
A sterile package protects an item only while its barrier remains intact under appropriate storage and handling conditions. Wetness, tears, punctures, and broken seals can compromise that barrier even when sterilization monitoring was satisfactory. Package inspection therefore addresses a different question from cycle monitoring. A compromised set should be removed from sterile use and managed through the applicable reprocessing procedure; an earlier acceptable cycle cannot repair a later barrier failure or make its contents suitable for aseptic handling.
Apply it
A wrapped instrument set falls onto a wet surface, and moisture reaches the wrapper. Set it aside for appropriate reprocessing and obtain an intact set, even though its sterilization record and chemical indicator were acceptable.
Common pitfall: Do not assume that a recent sterilization date overrides damage. Sterility maintenance depends on barrier integrity and handling events as well as the original cycle.
14.How should a refrigeration excursion be evaluated?
An excursion assessment reconstructs what the tissue experienced: the magnitude and duration of the deviation, affected inventory, measurement reliability, and applicable storage specifications. A normal reading after an alarm does not establish that prior exposure was acceptable. Temporarily control affected tissue while the evidence is reviewed. The disposition decision should connect actual exposure with validated storage conditions and product instructions, while the equipment investigation determines why the deviation occurred and whether the corrective action prevents recurrence.
Apply it
A refrigerator returns to its usual temperature after an overnight alarm. Identify the exposed tissues, preserve continuous temperature data, assess the full excursion, and document disposition before releasing inventory solely on the restored morning reading.
Common pitfall: A single spot temperature cannot reconstruct overnight conditions. Reassurance from the current display is weaker than a review of the complete exposure record.
15.How does anticipated exposure determine protective equipment?
Standard Precautions apply across donor handling activities because infectious risk is not reliably excluded by appearance or preliminary history. Select protective equipment according to anticipated contact with blood, body fluids, contaminated surfaces, or splashes. Gloves address hand exposure, while face and eye protection address splash pathways that gloves cannot cover. The decision should be linked to the task’s exposure routes, with safe handling practices maintained even when available testing is negative or the donor has no recognized infection.
Apply it
A recovery step is expected to splash blood toward the operator’s face. Add appropriate eye and face protection to the required attire rather than considering gloves sufficient because the donor’s initial infectious history is unremarkable.
Common pitfall: A low perceived infection risk does not eliminate exposure routes. Negative screening information cannot justify leaving an anticipated splash pathway unprotected during the procedure.
16.Why do glove changes require hand hygiene?
Gloves reduce contact exposure but do not replace hand hygiene. Hands can become contaminated during removal or through defects, and contaminated gloves can transfer microorganisms between surfaces. Perform hand hygiene at the appropriate transition, including after glove removal and before an aseptic task, then use the required clean or sterile gloves. The critical reasoning is to identify the change from contaminated activity to protected activity rather than assuming uninterrupted glove wear preserves an aseptic workflow.
Apply it
A technician handles a nonsterile telephone during setup and then prepares to touch sterile supplies. Stop the transition, remove contaminated gloves, perform appropriate hand hygiene, and don the required gloves before resuming the aseptic activity.
Common pitfall: Putting new gloves over contaminated gloves preserves the underlying problem and can contaminate the new pair during donning. Changing task conditions requires a deliberate hygiene transition.
17.What does environmental monitoring reveal about process control?
Environmental monitoring assesses conditions that could contaminate tissue or equipment, including microbial conditions where appropriate. Interpret results with sampling location, activity, timing, control limits, and trends. A rising pattern can reveal deterioration before an obvious product failure appears. Conversely, a negative sample does not establish that every exposed tissue is sterile. Monitoring must lead to investigation and corrective action when indicated; collecting results without evaluating their relationship to ongoing operations provides little practical quality protection.
Apply it
Repeated samples near an open processing area show increasing microbial recovery during busy shifts. Examine airflow, cleaning, traffic, and operator practices, assess affected processing periods, and verify improvement after the identified causes are corrected.
Common pitfall: Do not dismiss a consistent adverse trend because each individual result seems small. Process deterioration can become visible through repeated measurements before a single dramatic result.
18.When is process validation necessary?
Validation is needed when subsequent inspection and testing cannot fully verify the results of processing. It establishes documented evidence that a defined process consistently produces its intended result under specified conditions. Verification of an observable output and validation of a process are related but different activities. A satisfactory appearance in one finished tissue does not establish consistent control of an unobservable safety attribute. Changes to validated conditions require evaluation and revalidation when the change could affect the established result.
Apply it
A proposed process claims to reduce microbial transmission, but the claim cannot be confirmed by inspecting each finished graft. Require a properly designed, approved validation rather than relying on several visually clear trial tissues.
Common pitfall: A successful demonstration is not automatically validation. Evidence must address the intended claim, defined operating conditions, reproducibility, and appropriate approval.
19.How do audits and corrective actions improve reliability?
An audit systematically compares actual practice and records with applicable requirements and established procedures. A finding should lead to an investigation proportionate to its significance, correction of the immediate problem, and action addressing the underlying cause. Effectiveness review then asks whether the problem recurs. Repeatedly fixing individual records without examining a confusing form or flawed workflow can leave the cause intact. The strongest response connects evidence, cause, action, responsible implementation, and measurable evidence of sustained improvement.
Apply it
An audit finds missing preservation times across several shifts. Complete justified record corrections where possible, investigate how the form and workflow contributed, revise the process, and later sample records to determine whether completeness actually improved.
Common pitfall: Retraining everyone is tempting but may miss a system defect. Choose corrective action that addresses the demonstrated cause, then verify its effectiveness with relevant evidence.
20.How should microbiology results influence a tissue investigation?
A culture result must be interpreted in relation to what was sampled, when it was collected, the organism identified, the method used, and the tissue’s processing and distribution history. A positive environmental sample and a positive tissue-associated sample do not answer identical questions. Establish the possible connection to contamination and recipient risk rather than treating every result as interchangeable. A negative culture also has sampling and sensitivity limits and cannot independently establish the absence of all transmissible hazards.
Apply it
A laboratory reports microbial growth after a related tissue has been distributed. Confirm the specimen identity and result, determine which tissues and recipients may be connected, and communicate the information through the established investigation and notification process.
Common pitfall: An organism’s familiar name does not make it irrelevant. Its significance depends on the specimen, exposure pathway, tissue use, and clinical context of the investigation.
21.Which suspected adverse reactions require investigation and mandatory FDA reporting?
Under 21 CFR 1271.350(a), investigate any adverse reaction involving a communicable disease related to an HCT/P that the establishment made available for distribution. Mandatory FDA reporting applies when the reaction is fatal, life-threatening, causes permanent functional impairment or structural damage, or necessitates medical or surgical intervention, including hospitalization. Submit Form FDA-3500A within 15 calendar days of initially receiving the information. Investigate reported reactions as soon as practical; submit follow-up reports within 15 calendar days after receiving new information or as FDA requests. If information cannot be obtained, FDA may require a follow-up describing the attempts and reasons.
Apply it
A surgeon reports suspected graft-associated infection requiring hospitalization. Record when the information arrived, obtain clinical and microbiological details, and trace related tissue. The hospitalization meets a reportable outcome when the communicable-disease relationship applies; completing the causation investigation is not a prerequisite for meeting the initial reporting deadline.
Common pitfall: Investigation and mandatory reporting have different triggers. A reaction need not cause death to be reportable, and a preliminary report does not establish proven transmission. Do not postpone the initial report while awaiting final cultures or overlook follow-up obligations.
FDA Guidance for Industry: Current Good Tissue Practice and Additional Requirements for HCT/P Manufacturers · Federal Register :: Request Access
22.How does bidirectional tracking support a recall?
A tracking system must connect tissue from its donor to the consignee or final disposition and permit the reverse search. Distinct identification codes link the tissue with its records; code changes require a maintained relationship between old and new identifiers. During a recall investigation, the practical test is whether all related products can be located and their dispositions reconciled. Shipping records alone are insufficient if later transfers, use, return, or disposal cannot be linked back to the original donor.
Apply it
An infection report identifies one transplanted graft. Use its code to locate the donor, find every related distributed tissue, contact the relevant consignees, and reconcile whether each product was implanted, held, returned, or otherwise disposed of.
Common pitfall: A list of outgoing shipments is only part of traceability. The system must also work backward from an affected product and account for final disposition.
Donor-Related Issues20%
23.What establishes valid authorization for donation?
Authorization establishes the lawful basis for recovering and using donated tissue. Its validity depends on applicable law and the documented source, authority, scope, and circumstances of the anatomical gift. A hospital referral, an available donor, or a clinically suitable cornea does not itself establish authorization. Before recovery, reconcile the authorization record with donor identity and intended activities. Where records conflict, resolve the specific legal and factual discrepancy rather than assuming a universal family hierarchy applies in every jurisdiction.
Apply it
A referral identifies a potentially suitable donor, but the authorization record belongs to a similarly named person. Resolve identity and lawful authorization before recovery; clinical suitability and the referral cannot bridge the mismatch.
Common pitfall: Do not equate notification of a death with permission to recover tissue. Referral and authorization serve different purposes and require different supporting documentation.
24.How does authorization scope affect research and education?
The intended use of donated tissue must remain within the legally valid authorization. Transplantation, research, and education are distinct purposes that may be addressed differently in the authorization record. A tissue’s unsuitability for transplantation does not automatically permit an alternative use. Review the authorized purposes, restrictions, identity linkage, and disposition requirements before reassignment. This preserves the donor’s documented gift while allowing appropriate nonsurgical use when that use is actually supported by the applicable authorization.
Apply it
A cornea fails surgical evaluation, and a laboratory requests it for research. Check whether research is authorized and whether any restrictions apply before changing its designation and documenting the transfer to the research program.
Common pitfall: A useful educational opportunity does not expand an anatomical gift. Clinical rejection of a graft and authorization for another purpose are separate decisions.
25.How should a donor interview be reconciled with medical records?
The donor risk assessment interview supplies history that laboratory testing and a brief chart review may not reveal. Its value depends on an informed respondent, clear questions, documented answers, and follow-up of uncertainty. Compare the interview with available medical and other relevant records. A discrepancy should be investigated for its effect on eligibility rather than resolved by selecting the most reassuring answer. Negative test results cannot replace missing information about a risk or disease that screening is intended to detect.
Apply it
An interview reports no neurologic illness, but the hospital record describes rapidly progressive unexplained neurologic decline. Seek clarifying records and responsible review before completing screening, rather than accepting the interview as the sole account.
Common pitfall: An unanswered question is not a negative answer. Recording uncertainty accurately preserves the distinction between evidence that a risk is absent and information that remains unavailable.
FDA Guidance for Industry: Eligibility Determination for Donors of HCT/Ps
26.How can a concrete physical finding change donor screening?
Physical assessment supplies observable evidence that must be reconciled with the interview and medical records. FDA donor-eligibility guidance, section IV.G, identifies unexplained jaundice or icterus as findings associated with hepatitis B and hepatitis C. Document yellow discoloration objectively rather than diagnosing viral hepatitis from appearance. Review its onset, relevant history, documented clinical explanation, and donor screening test results. Negative testing does not independently erase unresolved clinical evidence. Conversely, an established alternative explanation matters: the guidance distinguishes unexplained findings from abnormalities whose nonviral cause is documented.
Apply it
Yellow skin is observed, but the initial interview contains no liver history. Record the observation and seek clinical records addressing jaundice, hepatitis history, bilirubin, and any established alternative cause. Combine that evidence with qualified infectious disease testing before the responsible person documents eligibility.
Common pitfall: Jaundice is a screening cue, not a diagnosis of hepatitis B or hepatitis C. Neither reassuring appearance nor a negative test can substitute for resolving relevant history and physical evidence.
FDA Guidance for Industry: Eligibility Determination for Donors of HCT/Ps · download · 21 CFR 1271.50 — Donor eligibility determination
27.When is a donor blood specimen collected for FDA testing?
For general HCT/P donor testing, 21 CFR 1271.80 permits collection at recovery or within seven days before or after recovery, with specified exceptions for other donor types. This general window does not by itself qualify a specimen. Identity, assay instructions, specimen condition, postmortem applicability, and possible plasma dilution remain relevant. Distinguish when the specimen was collected from when the laboratory performs the test; a timely collection can still be unsuitable for the intended assay or donor assessment.
Apply it
A premortem specimen was collected three days before corneal recovery. Its timing fits the general federal collection window, but verify donor linkage, specimen suitability, transfusion history, and assay requirements before accepting it for the required testing.
Common pitfall: Do not import a longer collection window from stem cell or oocyte donation into ordinary corneal donation. Exceptions belong to the donor categories specified in the regulation.
28.How do fluid type, administration time, and volume determine specimen qualification?
Transfusion or infusion can dilute circulating infectious markers. Under 21 CFR 1271.80(d)(2), suspected dilution sufficient to affect testing makes the donor ineligible unless an acceptable specimen collected before transfusion or infusion and within seven days before recovery is tested, or an appropriate algorithm evaluating volumes administered during the 48 hours before specimen collection establishes that significant dilution has not occurred. Explicit suspicion triggers include known or suspected blood loss in donors older than 12 years with more than 2,000 mL of blood/colloids within 48 hours or crystalloids within one hour, using death or specimen collection, whichever occurred earlier, as the window endpoint. Applicable combinations also matter. For donors 12 years or younger, any amount within these respective windows triggers suspicion regardless of blood loss. FDA guidance separately recommends avoiding specimens with greater than 50% dilution; that numerical recommendation is not the regulation's wording.
Apply it
Consider a 70-kg adult with blood loss, death at noon, and collection at 12:30. The complete administration record shows 1,500 mL red cells and 700 mL albumin within the preceding 48 hours, 600 mL saline at 11:30, and 2,500 mL saline completed at 10:00. Blood plus colloid totals 2,200 mL, triggering dilution assessment. In the FDA Appendix 2 example, blood is A = 1,500, colloid B = 700, and last-hour crystalloid C = 600 mL; the earlier saline falls outside C's window. Using the guidance's weight formulas, estimated plasma volume is 2,800 mL and blood volume approximately 4,667 mL. B + C = 1,300 does not exceed plasma volume, and A + B + C = 2,800 does not exceed blood volume, so this example algorithm supports acceptability for dilution. If last-hour saline instead totaled 3,000 mL, B + C = 3,700 would exceed plasma volume and the specimen would fail that algorithm.
Common pitfall: The 2,000-mL thresholds trigger assessment; they do not themselves calculate percentage dilution. Distinguish the regulation's 48-hour evaluation requirement from the fluid-specific windows in the example algorithm. Passing dilution assessment does not establish every other aspect of specimen or donor eligibility.
FDA Guidance for Industry: Eligibility Determination for Donors of HCT/Ps · 21 CFR 1271.80 — General requirements for donor testing · download
29.Which infectious agents, assays, and laboratory qualifications govern donor testing?
Start with the agent map: except where a regulatory exception applies, 21 CFR 1271.85(a) requires testing for HIV-1, HIV-2, hepatitis B virus, hepatitis C virus, and Treponema pallidum, whether the donated tissue is viable or nonviable. Additional categories have additional provisions: viable, leukocyte-rich tissue requires HTLV-I, HTLV-II, and CMV testing; reproductive tissue has genitourinary-agent provisions. These categories do not automatically make every additional test a corneal requirement. Section 1271.80(c) requires appropriate FDA-licensed, approved, or cleared donor screening assays used according to their instructions, cadaveric labeling when applicable and available, and a CLIA-certified laboratory or CMS-determined equivalent.
Apply it
Separate agent coverage from assay selection. For example, the August 2007 FDA guidance recommends HIV-1 antibody plus HIV-1 NAT and HCV antibody plus HCV NAT, distinguishing antibody detection from viral nucleic acid detection. Those are dated assay recommendations, whereas section 1271.85(a) names the agents. Verify that the selected testing arrangement covers each applicable agent with an appropriately qualified method.
Common pitfall: A familiar diagnostic test name does not establish donor-screening suitability. Likewise, the five-agent regulatory list is not a complete assay menu or a statement that every tissue category has identical testing requirements.
21 CFR 1271.80 — General requirements for donor testing · Federal Register :: Request Access · download
30.Why are screening and testing both necessary for eligibility?
Screening evaluates relevant history, risk factors, and clinical evidence, while testing examines specified infectious markers in a qualified specimen. The FDA eligibility determination integrates both. Negative testing cannot exclude every relevant disease or substitute for assessment of a significant clinical history. Similarly, a reassuring interview cannot replace required testing. Distinguish the question of whether the donor satisfies communicable disease eligibility criteria from whether a particular cornea has sufficient structural and cellular quality for a proposed operation.
Apply it
A donor’s required tests are nonreactive, but screening documents a relevant disqualifying communicable disease risk. Do not infer eligibility from the laboratory panel; integrate the screening finding into the responsible person’s documented determination.
Common pitfall: A completed panel is not a complete donor assessment. The requirements deliberately combine different kinds of evidence because their strengths and blind spots differ.
31.How does the syphilis testing exception differ from other reactive screens?
Under 21 CFR 1271.80, a reactive required communicable disease screening test generally makes the donor ineligible. A specified exception concerns a reactive nontreponemal syphilis screening test followed by a negative specific treponemal confirmatory test. This exception is test-specific and does not create a general rule that any negative supplemental result cancels any reactive screen. The remaining screening and testing requirements still need evaluation before the responsible person can establish and document the donor’s overall eligibility.
Apply it
A donor has a reactive nontreponemal syphilis screen and a negative specific treponemal confirmatory result. Recognize the federal exception while still reviewing every other eligibility element rather than automatically declaring the donor either eligible or ineligible.
Common pitfall: Do not generalize this exception to a reactive HIV or hepatitis donor screen. The regulation identifies a particular syphilis testing pattern, not unrestricted confirmatory overrides.
32.Why do rabies and prion concerns require clinical history?
The outline specifically includes rabies and transmissible spongiform encephalopathies among donor disease concerns. Routine negative blood screening does not independently exclude these hazards. A history of unexplained encephalitis, progressive neurologic illness, or a relevant exposure requires disease-specific review rather than reassurance from an unrelated viral panel. The discriminating principle is that a test result supports only the agents and specimen conditions it addresses; clinically significant evidence must remain part of the transplant safety assessment.
Apply it
A donor with unexplained fatal encephalitis has nonreactive routine infectious disease results. Identify the neurologic illness as unresolved safety information and prevent routine transplant release while the relevant history and applicable contraindications are assessed.
Common pitfall: Do not infer that every transmissible disease is covered by standard serology. Unrelated negative tests cannot resolve a specific clinical concern about neurologic infection or prion disease.
EBAA Exam Content Outline · EBAA Medical Standards — October 17, 2024
33.How does pending eligibility differ from determined ineligibility?
Pending eligibility means required information or review is incomplete; ineligibility is a completed determination based on applicable criteria. Tissue awaiting determination remains clearly identified in quarantine and distinguishable from released inventory. Shipment before completion does not eliminate quarantine and requires the specified accompanying records. These statuses cannot be merged into a generic hold that obscures why use is restricted. Limited regulatory exceptions have their own conditions and are not created by an ordinary request to meet a surgical schedule.
Apply it
A processing center requests a cornea while donor review remains incomplete. If shipment occurs, preserve quarantine status and the required accompanying statements, including that the eligibility determination is unfinished and ordinary transplantation must await completion.
Common pitfall: Moving a container is not releasing it for implantation. Geographic transfer and eligibility status are separate attributes that must remain clear throughout custody changes.
21 CFR 1271.60 — Quarantine before donor eligibility determination
34.Who documents eligibility, and how does it differ from suitability?
A responsible person must determine and document donor eligibility using the required screening and testing evidence. Eligibility addresses the relevant donor safety framework; surgical suitability additionally considers the individual tissue and intended graft use. A donor can meet communicable disease eligibility criteria while a cornea has a central scar or insufficient endothelial quality for a proposed operation. Apply FDA requirements and applicable EBAA contraindications to their proper questions rather than assuming either a clear cornea or an eligible donor establishes universal transplant suitability.
Apply it
The donor eligibility record is complete and acceptable, but microscopy identifies substantial central stromal pathology. Retain the eligibility conclusion while separately evaluating whether that cornea meets criteria for the intended surgical use.
Common pitfall: Do not edit an eligibility determination merely to express poor optical quality. Record donor eligibility and tissue suitability distinctly so each conclusion remains interpretable.
21 CFR 1271.50 — Donor eligibility determination · EBAA Medical Standards — October 17, 2024
Technical Procedures24%
35.How are donor identity and laterality protected during recovery?
Identity verification connects the person, authorization, specimen, recovered tissue, and records before an irreversible recovery step occurs. Laterality then distinguishes products from the same donor without breaking that shared donor linkage. Perform reconciliation at transitions where mix-ups could occur, including transfer into containers and handoff to another operator. A matching surname or location is insufficient when identifiers conflict. Once the chain becomes uncertain, stop the affected activity and resolve the discrepancy through documented evidence before continuing.
Apply it
The identification attached to the donor differs from the recovery packet by one identifier. Pause recovery, reconcile the discrepancy with authoritative records, and confirm that authorization and intended container labels belong to the same person.
Common pitfall: A plausible explanation is not an identity check. Assuming that a mismatch is a clerical typo can attach otherwise accurate testing to the wrong donor.
FDA Guidance for Industry: Current Good Tissue Practice and Additional Requirements for HCT/P Manufacturers · 21 CFR 1271.290 — Tracking
36.How does blood collection preserve specimen reliability?
Reliable blood collection combines the correct donor linkage, suitable collection materials, documented timing, and handling compatible with the intended tests. The collection record must let later reviewers relate the specimen to recovery, death, and relevant transfusions or infusions. A laboratory can analyze a tube without being able to repair an uncertain identity or undocumented collection history. Treat labeling and documentation as part of the collection procedure itself, because they preserve the meaning of the resulting laboratory measurements.
Apply it
A tube is found beside a recovery kit without a completed donor label. Do not assign it by proximity. Establish whether reliable contemporaneous evidence identifies the specimen, and obtain an appropriately identified replacement when that cannot be established.
Common pitfall: Testing an unidentified tube more extensively cannot restore its donor linkage. Analytical precision is useful only when the specimen’s origin and handling are adequately established.
FDA Guidance for Industry: Eligibility Determination for Donors of HCT/Ps · 21 CFR 1271.80 — General requirements for donor testing
37.Why is ocular surface preparation different from sterilizing a graft?
Ocular preparation reduces surface microbial burden before recovery while preserving tissue needed for transplantation. It does not establish that living tissue has become sterile. The approved method must control the agent, exposure, coverage, and any required removal while avoiding avoidable tissue injury. This creates two simultaneous objectives: reduce contamination risk and retain graft quality. A more aggressive treatment is not automatically safer if it damages the relevant cells or falls outside the validated preparation method.
Apply it
An operator proposes extending antiseptic exposure because the donor had substantial surface debris. Follow the approved preparation and escalation procedure, addressing the contamination concern without inventing a stronger exposure that may injure the graft.
Common pitfall: Do not transfer an instrument sterilization method to viable corneal tissue. Microbial reduction and preservation of living endothelial function require a tissue-appropriate validated approach.
38.What should happen after a sterile field breach?
A sterile field breach introduces an uncontrolled contact pathway between a nonsterile source and supplies or tissue. Identify the actual contact, stop the affected activity, remove or replace compromised items, and assess any tissue exposure under the established deviation procedure. Restoring the field and evaluating an already exposed graft are separate tasks. Simply wiping an instrument or changing gloves may correct one surface while leaving the tissue’s exposure unresolved. Document the event sufficiently to support a defensible disposition decision.
Apply it
A sterile forceps touches an unprepared surface and then contacts a corneoscleral rim. Replace the instrument, restore the field, and document and assess the tissue exposure rather than treating instrument replacement as complete resolution.
Common pitfall: A brief contact can still breach control. Duration alone does not establish that contamination failed to occur or that the tissue remains acceptable.
39.How do airflow protection and room control work together?
A controlled processing environment limits contamination through complementary controls: appropriate air filtration and flow, cleaning, equipment maintenance, staff practices, and monitoring. A hood protects a defined work zone, while the surrounding room and operator movements can affect that protection. Equipment placement or hands blocking clean airflow can undermine the intended arrangement. Evaluate the actual open-tissue activity and qualified workspace rather than assuming that the presence of a hood or a room called clean establishes adequate process conditions.
Apply it
During open-container work, supplies are stacked so that they interrupt the protective airflow path. Reconfigure the workspace according to its qualified operating arrangement and assess whether tissue was exposed while the intended protection was compromised.
Common pitfall: A room’s label is not performance evidence. Environmental protection depends on qualified conditions and correct use of the work zone during the actual operation.
21 CFR 1271.195 — Environmental control and monitoring · FDA Guidance for Industry: Current Good Tissue Practice and Additional Requirements for HCT/P Manufacturers
40.Why must processing workflow prevent donor-to-donor transfer?
Cross-contamination can move biological material between donors through shared instruments, surfaces, fluids, or handling. Mix-ups can also occur when multiple donor identities and labels occupy the same workspace. A controlled workflow separates donor activities, maintains clear identification, and resets the work area and supplies at defined transitions. The goal is not merely a tidy bench: it is preventing both infectious transfer and loss of identity. Negative donor test results do not remove the need for these process controls.
Apply it
Two donor sets are staged together to save time during open processing. Reorganize the work into the approved separated workflow, preserving donor-specific tools, containers, and records and completing the required reset between activities.
Common pitfall: Using different container colors cannot compensate for shared contaminated instruments. Identity separation and biological separation require coordinated controls across the complete workflow.
41.How do the stages and tissue-protection decisions differ between whole-eye recovery and corneal excision?
Both routes begin with identity and authorization checks, ocular inspection, antiseptic preparation, and a sterile field. A penlight or portable slit lamp reveals surface defects or contamination; sterile irrigation removes preparation solution before preservation. Whole-eye enucleation releases conjunctival and orbital attachments, including extraocular muscles and the optic nerve, while retaining the globe's scleral wall. Dissecting scissors divide attachments; forceps provide controlled traction without compressing the cornea. Corneal excision instead opens peripheral sclera and uses corneoscleral scissors to complete a circumferential cut, retaining a scleral handling rim. The disc is separated from underlying uveal attachments without contacting its endothelial surface. These are distinct anatomical operations even when both ultimately yield a corneal graft.
Apply it
An enucleated globe transitions into its labeled whole-eye preservation arrangement, such as a moist chamber, before any later laboratory disc excision. An in-situ disc transitions directly into corneal preservation medium. During laboratory excision, use the scleral rim for handling and protect the posterior cornea from instrument contact. Inspect rim integrity because later chamber mounting depends on an adequate peripheral seal.
Common pitfall: Do not confuse recovery with recipient trephination or assume that removing the globe also completes disc preparation. Exact incision placement, rim dimensions, antiseptic exposure, and preservation conditions are protocol-specific. The October 2024 EBAA standards are a historical edition; the official examination outline defines the full scope beyond this selective guide.
EBAA Exam Content Outline · EBAA Medical Standards — October 17, 2024 · University of Iowa: An Introduction to Corneal Transplantation · University of Iowa: Corneal Transplantation — From Donor to Recipient
42.Why must corneoscleral excision protect the endothelium?
The endothelial layer is a thin posterior cell sheet whose integrity matters when the intended graft must maintain corneal hydration. Direct contact, compression, or uncontrolled distortion during excision can damage that layer even if the disc remains grossly intact. Handling should therefore protect the transplantable surfaces and use the approved technique for peripheral support. A visually complete disc is only one processing outcome; the relevant cells and tissue architecture must also survive the recovery and preservation sequence.
Apply it
An excised disc has an intact outline, but the record describes accidental contact with its posterior surface. Preserve that information and assess the relevant endothelial region instead of accepting gross completeness as proof of an undamaged graft.
Common pitfall: A circular disc can still have important cellular injury. Anatomical completeness and preservation of endothelial quality are separate outcomes that both require attention.
University of Iowa: An Introduction to Corneal Transplantation · NEI: NIH-funded team identifies genetic underpinnings of Fuchs dystrophy
43.How does disc integrity affect later processing?
A recovered corneoscleral disc must preserve the anatomy required for its intended use and any planned processing equipment. Peripheral damage can matter even when the central cornea appears clear, particularly if the rim is needed to support mounting and a stable seal. Record the location and extent of cuts, tears, or other defects rather than reporting only central clarity. Subsequent suitability depends on whether the actual tissue can be handled and processed safely within the approved method.
Apply it
An in-situ disc has a peripheral tear near the area intended for chamber mounting. Before automated processing, determine whether it can meet the equipment’s validated mounting requirements rather than proceeding because its central optical zone looks clear.
Common pitfall: Peripheral tissue is not automatically expendable. A defect outside the optical zone can still interfere with fixation, pressure control, or reliable processing.
University of Iowa: Corneal Transplantation — From Donor to Recipient · FDA Guidance for Industry: Current Good Tissue Practice and Additional Requirements for HCT/P Manufacturers
44.Why are recovery and preservation times recorded separately?
Death, recovery, preservation, and later processing describe different events in the tissue’s history. Separate timestamps allow reviewers to reconstruct intervals and assess whether handling met the applicable method’s requirements. They also help interpret tissue quality and identify delays. A single time labeled procurement cannot reliably answer all these questions. Accurate documentation records what happened when, including uncertainties, rather than retrospectively assigning a convenient common time to events that occurred at different stages of the recovery and preservation sequence.
Apply it
A record shows recovery at 14:10 and preservation at 14:35. Calculate a 25-minute recovery-to-preservation interval and retain both original times so the separate death-to-recovery interval can also be assessed when needed.
Common pitfall: Do not substitute transport departure for preservation. These events may occur close together, but they describe different exposures and cannot be treated as equivalent timestamps.
45.Which recognizable scleral preservation approaches support structural graft use?
The historical October 2024 EBAA Medical Standards, E1.230, name ethanol at 70% or greater and sterile glycerol among scleral processing approaches. Ethanol preservation exposes structural tissue to alcohol; preparation for implantation must address residual preservative through the product's specified rinsing procedure. Glycerol preservation dehydrates tissue, making removal of glycerol and appropriate rehydration relevant before use. These preparations support scleral structural applications rather than preservation of functioning corneal endothelial cells. The named preservative does not, by itself, establish validated sterility, a universal storage temperature, or a universal expiration period.
Apply it
For an ethanol-preserved scleral patch and a glycerol-preserved patch, verify each product's preservation history and preparation instructions. Confirm completion of the specified washing or rehydration steps before implantation. Do not transfer those preparation steps to a viable endothelial graft simply because all three tissues originated in eyes.
Common pitfall: Preservative removal and restoration of handling characteristics are part of preparation for structural use. Do not infer that ethanol or glycerol maintains endothelial viability, or apply one storage limit to every scleral preparation. The cited standards identify historical approaches rather than universal current product instructions.
46.How does a microkeratome prepare a DSAEK graft?
Automated lamellar preparation uses a microkeratome with a mounted cornea, commonly on an artificial anterior chamber, to create a stromal cut. The posterior graft retains posterior stroma, Descemet membrane, and endothelium. Stable mounting and the device’s validated operating conditions matter because the cut depends on controlled tissue presentation. Equipment selection alone does not establish a satisfactory graft; the resulting tissue must be examined for the intended dimensions, integrity, and preservation of its relevant posterior layers after processing.
Apply it
A mounted cornea does not maintain the chamber conditions required by the approved cutting method. Correct or investigate the mounting problem before the pass rather than assuming the microkeratome will produce the intended plane regardless.
Common pitfall: The automated device controls only part of the process. Mounting, tissue condition, equipment setup, and postprocessing evaluation remain essential to a reliable preparation.
University of Iowa: Corneal Transplantation — From Donor to Recipient · University of Iowa: An Introduction to Corneal Transplantation
47.Why is DMEK preparation especially sensitive to tears and orientation?
A DMEK graft consists of Descemet membrane and attached endothelium without a supporting stromal layer. Its thinness makes controlled separation, tear recognition, and orientation especially important. A preparation may look small or delicate without being abnormal, but an actual tear can affect the usable graft area or integrity. Document the observed extent and location of damage and reassess the intended product. Preprocessing endothelial observations cannot establish that the layer remained undamaged throughout membrane separation and subsequent handling.
Apply it
During membrane separation, a tear extends toward the intended graft area. Document its location and extent, then evaluate whether the preparation still meets the intended product criteria rather than relying on its satisfactory prepeel appearance.
Common pitfall: Do not assess DMEK as though a stromal scaffold were present. The membrane-endothelium preparation has different handling vulnerabilities from a posterior stromal lenticule.
University of Iowa: An Introduction to Corneal Transplantation · FDA Guidance for Industry: Current Good Tissue Practice and Additional Requirements for HCT/P Manufacturers
48.When do processing changes require new evaluation?
A change in equipment, supplies, settings, or technique can affect both the intended processing result and other parts of the operation. Evaluate and approve the change before implementation, using verification or validation as appropriate. When an established validated process changes, assess whether revalidation is necessary. Product evaluation after processing answers whether the tissue meets its criteria; change control answers whether the revised method is adequately supported. Neither an attractive finished graft nor a familiar replacement component automatically resolves the other question.
Apply it
A supplier offers a replacement processing component with a different design. Compare its effects on the established method, complete the required evaluation and approval, and train operators before routine use instead of substituting it during a scheduled case.
Common pitfall: Calling a component equivalent does not establish process equivalence. Evaluate the features that can affect tissue contact, performance, contamination control, and the validated outcome.
Tissue-Related Procedures20%
49.How does slit lamp examination localize tissue abnormalities?
Slit lamp biomicroscopy helps distinguish epithelial, stromal, and posterior corneal findings by examining their location and depth. Record the nature, size, extent, and position of abnormalities rather than using a single label such as cloudy. The relationship to the intended graft area matters: a peripheral finding and a central deep stromal lesion can have different consequences. Evaluation should describe enough anatomy for suitability decisions, while avoiding the assumption that one optical appearance establishes either infection or endothelial function.
Apply it
A cornea has a small peripheral opacity and a separate central stromal lesion. Document each finding’s location, depth, and dimensions so the evaluator can relate them to the proposed graft diameter and retained layers.
Common pitfall: A generic clear-or-cloudy classification loses important information. Depth and location can be decisive when different operations transplant different portions of the same cornea.
University of Iowa: Corneal Transplantation — From Donor to Recipient · EBAA Medical Standards — October 17, 2024
50.How is endothelial cell density calculated and qualified?
Endothelial cell density expresses the number of counted cells per unit area, commonly cells per square millimeter. For a defined counting area, divide the accepted cell count by that area. The calculation is meaningful only if calibration, boundary identification, counting rules, and image selection are reliable. A precise numerical output can still be biased by a poor image or an unrepresentative field. Density contributes to suitability assessment but does not independently prove normal pump function or establish a universal acceptance threshold.
Apply it
An acceptable counting frame contains 120 cells across 0.05 square millimeter. Calculate 120 divided by 0.05, or 2,400 cells/mm², then review image quality and representativeness before using the value in tissue assessment.
Common pitfall: Do not confuse total counted cells with density. The same count implies different densities when the analyzed areas differ, so area and calibration are essential.
University of Iowa: Corneal Transplantation — From Donor to Recipient · EBAA Medical Standards — October 17, 2024
51.What do endothelial size and shape variations indicate?
Polymegathism describes variation in endothelial cell size, while pleomorphism describes variation in cell shape. These features, cell loss, and guttae add information beyond a density value. Specular microscopy characterizes a sampled endothelial mosaic; it is a surrogate assessment rather than a direct measurement of the entire graft’s physiological performance. Interpret morphology with image quality, sampled location, density, and other corneal findings. Two tissues with similar calculated densities can therefore warrant different assessments when their observed cell patterns differ substantially.
Apply it
Two samples produce similar cell densities, but one shows pronounced variation in cell size and shape. Describe the morphological differences and assess their relevance rather than reporting the density values as evidence that the tissues are equivalent.
Common pitfall: A satisfactory count does not erase abnormal morphology. Conversely, one poorly resolved image should not be treated as definitive evidence of widespread endothelial disease.
University of Iowa: Corneal Transplantation — From Donor to Recipient
52.How do PK and DALK differ in the layers transplanted?
Penetrating keratoplasty replaces a full-thickness corneal segment, including donor endothelium. Deep anterior lamellar keratoplasty replaces anterior tissue while retaining the recipient’s Descemet membrane and endothelium. The distinction links recipient pathology to donor requirements: anterior stromal disease with a healthy recipient endothelium can support an anterior lamellar approach, whereas combined anterior and posterior disease may require another strategy. Do not assume that endothelial criteria for a full-thickness optical graft automatically answer suitability for every anterior lamellar application.
Apply it
A surgeon plans DALK for stromal disease and documents healthy recipient endothelium. Identify the recipient posterior layers that remain and explain why donor anterior tissue quality is central to the requested graft assessment.
Common pitfall: DALK is not a thin full-thickness transplant. Retention of recipient Descemet membrane and endothelium is the key anatomical distinction from penetrating keratoplasty.
University of Iowa: An Introduction to Corneal Transplantation
53.Which layers distinguish DSAEK from DMEK?
DSAEK supplies posterior stroma, Descemet membrane, and endothelium. DMEK supplies Descemet membrane and endothelium without posterior stroma. Both address endothelial replacement, but their composition creates different preparation and handling characteristics. Identify the requested product from the layers rather than the shared purpose of treating endothelial dysfunction. A posterior stromal lenticule is not interchangeable with a membrane-only graft, and a processing record should establish which preparation was actually produced before labeling and distribution.
Apply it
An order requests a membrane-only endothelial graft, but the prepared product includes posterior stroma. Recognize that the product composition corresponds to DSAEK rather than DMEK and resolve the discrepancy before distribution to the surgeon.
Common pitfall: Endothelial keratoplasty is a family of procedures. Sharing a target cell layer does not make the graft compositions, thicknesses, or preparation methods identical.
University of Iowa: An Introduction to Corneal Transplantation
54.How does intended graft function change tissue selection?
An optical corneal graft, a structural patch, and a keratolimbal allograft serve different purposes. Optical graft selection emphasizes the relevant transparent layers and, when transplanted, endothelial quality. A structural graft supports or covers tissue, while a keratolimbal graft includes the limbal region for ocular surface reconstruction. The tissue’s intended function determines which anatomy and properties must be preserved. A product unsuitable for one use is not automatically suitable for another; each designation still requires the appropriate safety and tissue assessment.
Apply it
A request for limbal tissue is filled with a central corneal button lacking the limbal region. Identify the anatomical mismatch and obtain a product containing the requested tissue rather than assuming any corneal graft can serve the purpose.
Common pitfall: Do not call all nonspecific tissue requests patch grafts. Clarify whether the surgeon needs optical, structural, endothelial, or limbal tissue before selecting the product.
EBAA Exam Content Outline · EBAA Medical Standards — October 17, 2024
55.How are storage conditions and expiration assigned?
Storage conditions and expiration must be supported for the actual tissue, preservation method, container, and processing history. The expiration of an unopened storage reagent is not automatically the expiration of tissue placed into that reagent. Likewise, changing a medium does not by itself erase prior tissue age or exposure. Review the applicable instructions and validated dating method, keeping the tissue’s complete history intact. The release decision should use the assigned product expiration and acceptable storage record, not an assumed universal corneal shelf life.
Apply it
A storage solution bottle remains within its reagent expiration date, but the preserved cornea has reached its assigned tissue expiration. Do not extend the graft’s dating merely because the original solution bottle was still usable.
Common pitfall: Reagent dating and tissue dating answer different questions. A fresh container or medium cannot independently reset the supported expiration of an already preserved graft.
56.What must accurate tissue labeling accomplish?
Labeling must identify the actual tissue and prevent mix-ups while preserving its linkage to the donor and records. The outline includes ISBT 128, a standardized system supporting identification and product description. Standardized coding does not replace verification of label accuracy, legibility, integrity, product identity, and applicable status information. A readable barcode can faithfully encode an incorrect selection. The verification process therefore checks the relationship between the physical product, human-readable information, encoded information, and supporting records before distribution.
Apply it
A label scans successfully, but its product description identifies an unprocessed cornea while the container holds a processed endothelial graft. Correct the product identification through controlled labeling procedures and reverify the tissue-to-record linkage before release.
Common pitfall: Successful scanning proves that data can be read, not that the data describe the correct product. Physical identity and encoded meaning both require verification.
EBAA Exam Content Outline · 21 CFR Part 1271 — April 1, 2025 annual edition
57.Which records distinguish release from transfer in quarantine?
Accompanying documentation communicates the tissue’s identity and the eligibility status relevant to its permitted handling or use. Completed eligibility records and a transfer made before completion describe different situations. A quarantine shipment must retain the required identification and statements that determination is incomplete and ordinary implantation must await completion. A container arriving at a surgical facility is not automatically ready for transplantation. Review the actual release status and required records rather than inferring authorization to use tissue from its physical delivery.
Apply it
A cornea arrives with an identifier and a statement that donor eligibility remains incomplete. Keep it under the specified restrictions and obtain the completed determination and appropriate release information before treating the delivery as a routine transplant-ready product.
Common pitfall: The shipping destination does not change regulatory status. A quarantined product can reach another establishment while remaining unavailable for ordinary implantation or transplantation.
21 CFR 1271.60 — Quarantine before donor eligibility determination · 21 CFR Part 1271 — April 1, 2025 annual edition
58.How does packaging protect tissue during transport?
Transport packaging must protect container integrity, identity, and the conditions required by the tissue’s validated shipping method. Mechanical protection and temperature control solve different problems, and both can fail independently. A container that arrives unbroken may still have an unacceptable exposure history; a satisfactory temperature record does not repair leakage or a broken seal. Assess the package, product, labels, and available transport evidence together, relating findings to the actual shipping configuration and the conditions it was designed to maintain.
Apply it
A shipment arrives at an acceptable recorded temperature, but fluid is visible outside the primary container. Hold the tissue and assess the apparent integrity failure rather than allowing the temperature record to override evidence of leakage.
Common pitfall: Adding more coolant is not automatically protective. A shipping method must maintain the intended conditions without creating an unsupported temperature exposure or damaging the tissue.
59.When can returned tissue be considered for redistribution?
Returned tissue requires a documented assessment before it can reenter available inventory. Establish its identity, custody, storage and transport conditions, container integrity, expiration, and any handling that could affect safety or quality. An intact seal provides useful evidence but does not establish the complete exposure history. If required conditions cannot be demonstrated, the missing evidence cannot be replaced by an assumption that the package probably remained acceptable. Return evaluation should also preserve tracking to the prior consignee and final disposition.
Apply it
A surgery is canceled and an unopened graft returns without any reliable storage record for its time away. Keep it out of released inventory while evaluating the missing evidence and apply the established disposition criteria.
Common pitfall: Unused does not mean unchanged. A graft may retain an intact seal while having an undocumented or unacceptable temperature history that prevents routine redistribution.
60.How should nonsurgical tissue remain safely distinguishable?
Research and educational tissue should remain clearly identified for its authorized purpose and controlled so it cannot be mistaken for released transplant tissue. Preserve donor linkage, relevant hazard information, and disposition records even when optical or endothelial acceptance criteria differ from surgical use. A change in intended use does not erase the tissue’s history. The practical decision is whether the proposed activity is authorized and supported, with handling and identification that prevent accidental clinical use and communicate relevant risks to recipients of the material.
Apply it
A teaching laboratory receives a cornea unsuitable for transplantation. Confirm educational authorization, clearly identify its nonsurgical status, communicate relevant handling information, and record the transfer so the material cannot accidentally return to transplant inventory.
Common pitfall: A research label is not a substitute for authorization or traceability. Alternative use changes the purpose, while essential identity and hazard information still matter.
What to focus on during revision
The following are CertMedbry study suggestions. Use the official outline to check the full scope of your examination.
- Separate donor eligibility, tissue suitability, processing acceptance, and final release; identify the evidence required for each decision.
- Prioritize Quality Assurance and Control and Technical Procedures, which together account for 48% of the official blueprint.
- Connect corneal anatomy to PK, DALK, DSAEK, DMEK, structural grafts, and limbal tissue requests.
- Practise specimen qualification, plasma dilution assessment, reactive screening interpretation, and quarantine status under the United States FDA framework.
- Trace identity, laterality, process changes, temperature exposures, and tissue disposition across every handoff.
- Use the official outline to extend study to its complete scope, including CMS Conditions of Participation, disease-specific contraindications, and additional surgical applications.
A practical preparation plan
1. Map the complete outline
Create a study map using the five official domain names and weights. Mark each listed subtopic as understood, uncertain, or unstudied. Use this guide to build reasoning, then address remaining outline topics with the issuer’s recommended references.
2. Draw the layers and grafts
Draw the five corneal layers from memory. Shade the donor layers used in PK, DALK, DSAEK, and DMEK, and identify which recipient layers remain. Explain how a defect in each layer changes the relevant tissue assessment.
3. Work a donor case from authorization to determination
For a hypothetical donor, reconcile identity, authorization, interview, physical assessment, records, specimen timing, dilution assessment, and required testing. State what remains incomplete and whether the tissue belongs in quarantine before documenting a determination.
4. Rehearse technical decision points
Review recovery and processing with a qualified trainer. Explain the purpose of each control, including sterile transitions, endothelial protection, mounting, and postprocessing evaluation. Prepare separately for the witnessed practical demonstration required by the CEBT pathway.
5. Investigate deviations with evidence
Practise a refrigeration excursion, sterile field breach, identity discrepancy, and recipient infection report. For each, identify affected tissue, immediate controls, missing evidence, disposition criteria, root cause, and a meaningful effectiveness check.
6. Use the drills to diagnose learning needs
Answer all 20 questions before reviewing explanations. For each error, explain why the tempting alternative fails and record the underlying principle. Revisit the flashcards using spaced recall and return to the relevant official topic when reasoning remains uncertain.
Use your sample score as a starting point
The free set contains 20 original practice questions. It is a small learning sample, not an official examination or a validated pass prediction. Review each explanation and its source before moving to another topic.
Start the free sampleOfficial sources and updates
- EBAA Certification Exam
- EBAA Criteria for Certification and Recertification of Eye Bankers
- EBAA Exam Content Outline
- Eye Banker Certification Examination: Exam Resource Document & Study Guide
- CEBT Exam Content Outline
- EBAA Medical Standards / Procedures Manual
- EBAA Medical Standards — October 17, 2024
- EBAA Accreditation Governance and Functions
- FDA Guidance for Industry: Current Good Tissue Practice and Additional Requirements for HCT/P Manufacturers
- FDA Guidance for Industry: Eligibility Determination for Donors of HCT/Ps
- 21 CFR 1271.50 — Donor eligibility determination
- 21 CFR 1271.60 — Quarantine before donor eligibility determination
- 21 CFR 1271.80 — General requirements for donor testing
- 21 CFR 1271.195 — Environmental control and monitoring
- 21 CFR 1271.290 — Tracking
- 21 CFR Part 1271 — April 1, 2025 annual edition
- CDC Recommendations for Disinfection and Sterilization in Healthcare Facilities
- CDC Sterilizing Practices
- CDC Standard Precautions for All Patient Care
- CDC Clinical Safety: Hand Hygiene for Healthcare Workers
- NEI: NIH-funded team identifies genetic underpinnings of Fuchs dystrophy
- National Eye Institute: Presbyopia
- National Eye Institute: How the Eyes Work
- University of Iowa: Laser Refractive Surgery — Anatomy
- University of Iowa: An Introduction to Corneal Transplantation
- University of Iowa: Corneal Transplantation — From Donor to Recipient
- download
- Federal Register :: Request Access
- Federal Register :: Request Access
Confirm current eligibility, fees, scheduling and policies directly with the examination provider. CertMedbry is independent and is not endorsed by these organisations. How we handle content and corrections.